Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

OcuMedic, Inc.

OcuMedic’s solution is continuous dosing using contact lens with visual correction or a plano contact bandage replacing eye drops providing more efficacious and convenient therapy DECREASING COMPLICATIONS and reducing HEALTH CARE COSTS.

  • Date:Tuesday, February 12
  • Time:10:15 AM - 10:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:22452
  • Goal for Presentation:seeking investors and strategic partners
  • Company Website:OcuMedic.net
  • Company HQ City:Mullica Hill
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$1,850,000.
  • Size of Last Investment Round:$4,000,000.
  • Previous and Current Investors:NIH / NSF Roan University Investment Fund
  • CEO/Top Company Official:Keith D. Ignotz, President & CEO
  • Year Founded:2007
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:Timed delivery of bromfenac (NSAID) anti inflammatory from corneal bandage replacing eye drops
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Three (3)
  • Additional Information/Comments:OcuMedic’s method, memory for the drug is produced during polymer synthesis where monomers are complexed non-covalently to the drug and crosslinked into a hydrogel matrix. Upon removal of the drug, macromolecular memory sites remain within the hydrogel with affinity for the drug. The drug’s heightened interaction with these memory pockets enhances its loading and SLOWS its transport within the hydrogel despite comparable free volume of drug transport. It has been shown that the extension of release has a strong dependence on mimicking biological recognition in the design exploiting the chemical diversity and amounts of monomers in relation to the drug. Thus OcuMedic’s can literally….. DIAL IN THE RELEASE OF DRUG FROM THE LENS OVER TIME delivering a therapeutic concentration of drug payload for the duration of wear.
Speakers
Keith D. Ignotz
OcuMedic, Inc.
Back